American Oncology Network, LLC | Strategic Alliance Partners

Developments may soon impact clinical practice in hematology and oncology.

AON receives ranking no. 107 among America’s fastest-growing private companies and no. eight among health services.

The new proposal will have grave effects on the sustainability of community oncology practices.

American Oncology Network, LLC in-house specialty pharmacy is pleased to announce that it has successfully completed reaccreditation through Accreditation Commission for Health Care for specialty pharmacy services.

Advice for clinical pharmacists who help manage patients with relapsed/refractory multiple myeloma in the current era of novel therapies and recommendations to improve upon current practice patterns.

Novel treatment strategies being explored in clinical trials that look exciting in relapsed/refractory multiple myeloma, and implications for using these newer approaches in the future.

The importance of coordinated care and proper education to pharmacists on best practices when dispensing anti-BMCA therapy to patients with relapsed/refractory multiple myeloma.

Robert Mancini, PharmD, BCOP, FHOPA, of St. Luke’s Cancer Institute: Boise, comments on his experience navigating challenges using belantamab mafodotin, an anti-BCMA therapy, to treat relapsed/refractory multiple myeloma.

Recommendations for managing patients who receive belantamab mafodotin, an anti-BCMA therapy, for relapsed/refractory multiple myeloma, with special considerations regarding the ocular health of patients.

Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.

Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.

Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.

Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.

Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.

A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.